Dr. Mario Saltarelli, Director of Bioasis Technologies (BTI.V) talks about the company’s ground-breaking xB3 platform which allows therapeutic drugs to pass through the seemingly impenetrable blood-brain barrier, providing an effective treatment methodology for such neurological disorders as Alzheimer’s disease, Lewy Body Dementia and Parkinson’s. In short, Bioasis’ final frontier solution could very well revolutionize medical science, potentially helping to heal the one billion people suffering from neurological disorders worldwide. Tune in!
Bioasis Technologies (BTI.V): First Glance With Jody Vance (Ep 62)
Latest Articles
- Standard Uranium (STND.V): Now a triple threat as Sprott goes nuclear on uranium buy
- Zefiro Methane Corp (ZEFI.CBOE): Caps orphaned oil wells, cleans the environment, and makes money
- Victory lap: Five companies we told you about and how far up they’ve gone since
- Standard Uranium (STND.V) coverage sees stock rise 90% in three days
- The promo engine is revving on Magma Silver (MGMA.V)
Top Searches
Abitibi Greenstone Belt Barrick Gold best canadian cannabis company biotech Bitcoin blockchain bullion Canada cannabis CBD China Chris Parry covid cryptocurrency DEFN.V Fraser Institute gambling Gold gold price. gold prices Greg Nolan hemp inflation interest rates investing investments lithium Lukas Kane marijuana mining money Newmont Goldcorp Nexus Gold pharmaceuticals psychedelics resources shrooms stock market stocks technology trading uranium wealth wealth creation weed
by
Leave a Reply